Selective sulfonation of benzodiazepine derivatives
AssigneeImmunoGen, Inc.
InventorsScott A. Hilderbrand, Benjamin M. Hutchins
Life of this patent
Estimating the term…
Abstract
The invention relates to novel methods of preparing cell-binding agent-cytotoxic agent conjugates, wherein the cytotoxic agent is an imine-containing cytotoxic agent bearing a maleimide group. In some embodiments, the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an engineered Cys, such as an engineered Cys in the heavy chain CH3 domain, at a position corresponds to the EU/OU numbering position 442 (or C442) on an antibody CBA. The invention also provides conjugates prepared by the methods of the present invention, compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of the invention.
Claims29
A method of preparing a cell-binding agent-cytotoxic agent conjugate comprising the steps of:
- (a) reacting an imine-moiety in an imine-containing cytotoxic agent represented by the following formula:
- or a pharmaceutically acceptable salt thereof, with sulfur dioxide, a bisulfite salt or a metabisulfite salt in an aqueous solution at a pH of 1.9 to 5.0 to form a modified cytotoxic agent comprising a modified imine moiety represented by the following formula:
- or a pharmaceutically acceptable salt thereof;
- and
- (b) reacting the modified cytotoxic agent with a cell-binding agent to form the cell-binding agent-cytotoxic agent conjugate,
- wherein:
- wherein:
- L″ and L′″ are both —H;
- L′ is represented by the following formula:
- —NR5—P1—C(≡O)—(CRaRb)s—C(≡O)— (B1′)
- wherein:
- Ra and Rb, for each occurrence, are each independently —H, (C1-C3)alkyl or a charged substituent or an ionizable group Q;
- R5 is —H or an optionally substituted linear or branched alkyl having 1 to 10 carbon atoms;
- P1 is an amino acid residue or a peptide containing between 2 to 20 amino acid residues;
- and
- s is an integer from 1 to 6;
- R1, R2, R3, R4, R1′, R2′, R3′, and R4′ are all —H;
- R6 is OMe;
- X1′ and Y1′ are both —H;
- and
- A and A′ are —O—;
- and
- L is represented by the following structural formula:
- or a pharmaceutically acceptable salt thereof, wherein:
- s1 is the site covalently linked to D;
- s2 is the site covalently linked to the maleimide group;
- R23 and R24, for each occurrence, are independently H or an optionally substituted alkyl;
- m′ is an integer between 0 and 10;
- and
- Rh′ is H or an optionally substituted alkyl.
2-12. (canceled)
14-19. (canceled)
23-25. (canceled)
(canceled)
31-47. (canceled)
(canceled)
56-66. (canceled)
(canceled)
72-167. (canceled)
Dependencies are inferred from the claim text.